MEDIMMUNE, INC. BREAKS GROUND ON NEW BIOLOGICS MANUFACTURING FACILITY IN FREDERICK, MARYLAND, A $250-MILLION EXPANSION

MedImmune, Inc. announced its official groundbreaking to expand the biologics manufacturing facility at its existing site in Frederick, Maryland. MedImmune's Synagis (palivizumab), the first monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) to help prevent an infectious disease, is currently produced at the site. The $250-million expansion is the first phase of a multi-phase construction project that MedImmune announced last fall.
BioSpace